SG&A Expense Trends: Axsome Therapeutics vs. ImmunityBio

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. Over the past decade, Axsome Therapeutics, Inc. and ImmunityBio, Inc. have shown significant shifts in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Axsome's SG&A expenses skyrocketed by over 23,000%, reflecting its aggressive growth strategy and increased operational activities. In contrast, ImmunityBio's expenses peaked in 2015, with a notable 5,000% increase from the previous year, before stabilizing in recent years.

Key Insights

• Axsome Therapeutics: The company's SG&A expenses surged, particularly from 2021 to 2023, indicating a strategic expansion phase.
• ImmunityBio: After a dramatic rise in 2015, the company maintained a steady expenditure pattern, suggesting a focus on operational efficiency.

These trends highlight the contrasting financial strategies of two leading biotech firms, offering valuable insights for market analysts and investors.